514. Anti-SARS-CoV-2 Monoclonal Antibodies for Early COVID-19: A Real World Experience

BACKGROUND: Anti-SARS-CoV-2 monoclonal antibodies afford prompt immunity, have demonstrated reduction in severe COVID-19 in high risk ambulatory patients, and are available through Emergency Use Authorization. Challenges exist, however, to widespread utilization. METHODS: This operations study 11/23...

Descripción completa

Detalles Bibliográficos
Autores principales: Belden, Katherine, Hess, Bryan, Brugger, Caroline, Carr, Rachel, Braun, Todd, DeRose, Joseph L, Zurlo, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690787/
http://dx.doi.org/10.1093/ofid/ofab466.713

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690787/
http://dx.doi.org/10.1093/ofid/ofab466.713

Ejemplares similares